drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01015 | DB08868 | 1,247 | 1,011 | [
"DDInter1724",
"DDInter737"
] | Sulfamethoxazole | Fingolimod | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Minor | 0 | [
[
[
1247,
23,
1011
]
],
[
[
1247,
6,
8374
],
[
8374,
45,
1011
]
],
[
[
1247,
21,
28792
],
[
28792,
60,
1011
]
],
[
[
1247,
62,
112
],
[
11... | [
[
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fingolimod"
]
],
[
[
"Sulfamethoxazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (C... | Sulfamethoxazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fingolimod (Compound)
Sulfamethoxazole (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Fingolimod (Compound)
Sulfamethoxazole may cause a minor interaction that can limit clin... |
DB00241 | DB06228 | 288 | 792 | [
"DDInter257",
"DDInter1609"
] | Butalbital | Rivaroxaban | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Moderate | 1 | [
[
[
288,
24,
792
]
],
[
[
288,
23,
752
],
[
752,
24,
792
]
],
[
[
288,
24,
79
],
[
79,
24,
792
]
],
[
[
288,
24,
466
],
[
466,
63,
... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Butalbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
... | Butalbital may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafeni... |
DB00911 | DB14975 | 458 | 988 | [
"DDInter1811",
"DDInter1949"
] | Tinidazole | Voxelotor | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Moderate | 1 | [
[
[
458,
24,
988
]
],
[
[
458,
24,
309
],
[
309,
24,
988
]
],
[
[
458,
63,
63
],
[
63,
24,
988
]
],
[
[
458,
24,
913
],
[
913,
25,
... | [
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
... | Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Teniposide and Tenip... |
DB04865 | DB08879 | 4 | 632 | [
"DDInter1335",
"DDInter173"
] | Omacetaxine mepesuccinate | Belimumab | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor. BLyS levels are often elevated in immunodeficient and autoimmune disorders, such as systemic lupus erythematosus (SLE).[A2... | Moderate | 1 | [
[
[
4,
24,
632
]
],
[
[
4,
24,
713
],
[
713,
63,
632
]
],
[
[
4,
63,
1184
],
[
1184,
24,
632
]
],
[
[
4,
24,
1683
],
[
1683,
24,
... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belimumab"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Belimumab
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate dis... |
DB00333 | DB11986 | 576 | 484 | [
"DDInter1166",
"DDInter648"
] | Methadone | Entrectinib | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Major | 2 | [
[
[
576,
25,
484
]
],
[
[
576,
23,
112
],
[
112,
23,
484
]
],
[
[
576,
24,
222
],
[
222,
23,
484
]
],
[
[
576,
25,
774
],
[
774,
24,... | [
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Methadone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Methadone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Methadone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibu... |
DB01076 | DB11901 | 700 | 913 | [
"DDInter133",
"DDInter107"
] | Atorvastatin | Apalutamide | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
700,
24,
913
]
],
[
[
700,
63,
112
],
[
112,
23,
913
]
],
[
[
700,
64,
600
],
[
600,
24,
913
]
],
[
[
700,
62,
303
],
[
303,
24,... | [
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Atorvastatin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole... |
DB00242 | DB01073 | 1,064 | 1,488 | [
"DDInter392",
"DDInter745"
] | Cladribine | Fludarabine | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Major | 2 | [
[
[
1064,
36,
1488
]
],
[
[
1064,
40,
1049
],
[
1049,
1,
1488
]
],
[
[
1064,
1,
325
],
[
325,
1,
1488
]
],
[
[
1064,
25,
1426
],
[
1426,
... | [
[
[
"Cladribine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Fludarabine"
]
],
[
[
"Cladribine",
"{u} (Compound) resembles {v} (Compound)",
"Regadenoson"
],
[
"Regadenoson"... | Cladribine (Compound) resembles Fludarabine (Compound) and
Cladribine (Compound) resembles Regadenoson (Compound) and Regadenoson (Compound) resembles Fludarabine (Compound)
Cladribine (Compound) resembles Nelarabine (Compound) and Nelarabine (Compound) resembles Fludarabine (Compound)
Cladribine may lead to a major li... |
DB00549 | DB08886 | 522 | 637 | [
"DDInter1955",
"DDInter126"
] | Zafirlukast | Asparaginase Erwinia chrysanthemi | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
522,
24,
637
]
],
[
[
522,
24,
392
],
[
392,
24,
637
]
],
[
[
522,
63,
491
],
[
491,
24,
637
]
],
[
[
522,
24,
159
],
[
159,
63,... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"La... | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB01128 | DB11986 | 918 | 484 | [
"DDInter204",
"DDInter648"
] | Bicalutamide | Entrectinib | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
918,
24,
484
]
],
[
[
918,
62,
1247
],
[
1247,
23,
484
]
],
[
[
918,
23,
271
],
[
271,
23,
484
]
],
[
[
918,
23,
907
],
[
907,
6... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Bicalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],... | Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Mirabegron... |
DB00790 | DB09481 | 664 | 460 | [
"DDInter1431",
"DDInter1113"
] | Perindopril | Magnesium carbonate | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Minor | 0 | [
[
[
664,
23,
460
]
],
[
[
664,
24,
401
],
[
401,
23,
460
]
],
[
[
664,
63,
999
],
[
999,
23,
460
]
],
[
[
664,
1,
954
],
[
954,
23,
... | [
[
[
"Perindopril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
... | Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Thiethyl... |
DB00279 | DB00375 | 1,152 | 1,037 | [
"DDInter1074",
"DDInter433"
] | Liothyronine | Colestipol | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Bile acid sequestrants like colestipol have been in use since the 1970s.[FDA Label, F4555, F4567, L6262] And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia, colestipol is still generally o... | Moderate | 1 | [
[
[
1152,
24,
1037
]
],
[
[
1152,
21,
29118
],
[
29118,
60,
1037
]
],
[
[
1152,
24,
126
],
[
126,
62,
1037
]
],
[
[
1152,
23,
467
],
[
467... | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colestipol"
]
],
[
[
"Liothyronine",
"{u} (Compound) causes {v} (Side Effect)",
"Tachycardia"
],
[
"Tachycardia",
"{u} (Side Effect)... | Liothyronine (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Colestipol (Compound)
Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Coles... |
DB00196 | DB00214 | 600 | 1,028 | [
"DDInter743",
"DDInter1836"
] | Fluconazole | Torasemide | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Moderate | 1 | [
[
[
600,
24,
1028
]
],
[
[
600,
6,
6017
],
[
6017,
45,
1028
]
],
[
[
600,
21,
28680
],
[
28680,
60,
1028
]
],
[
[
600,
25,
1347
],
[
1347,... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Torasemide"
]
],
[
[
"Fluconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)... | Fluconazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Torasemide (Compound)
Fluconazole (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Torasemide (Compound)
Fluconazole may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may cause a m... |
DB00675 | DB01218 | 888 | 1,493 | [
"DDInter1744",
"DDInter852"
] | Tamoxifen | Halofantrine | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Major | 2 | [
[
[
888,
25,
1493
]
],
[
[
888,
6,
3486
],
[
3486,
45,
1493
]
],
[
[
888,
7,
5998
],
[
5998,
46,
1493
]
],
[
[
888,
18,
2183
],
[
2183,
... | [
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Tamoxifen",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Halofan... | Tamoxifen (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Halofantrine (Compound)
Tamoxifen (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Halofantrine (Compound)
Tamoxifen (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Halofantrine (Compound)
Tamoxifen (... |
DB00081 | DB00758 | 273 | 1,347 | [
"DDInter1838",
"DDInter413"
] | Tositumomab | Clopidogrel | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Major | 2 | [
[
[
273,
25,
1347
]
],
[
[
273,
25,
1018
],
[
1018,
25,
1347
]
],
[
[
273,
23,
539
],
[
539,
62,
1347
]
],
[
[
273,
25,
1338
],
[
1338,
... | [
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"... | Tositumomab may lead to a major life threatening interaction when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Clopidogrel
Tositumomab may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interact... |
DB09054 | DB11757 | 384 | 960 | [
"DDInter905",
"DDInter994"
] | Idelalisib | Istradefylline | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. This region of the brain is highly in... | Major | 2 | [
[
[
384,
25,
960
]
],
[
[
384,
64,
1135
],
[
1135,
23,
960
]
],
[
[
384,
63,
77
],
[
77,
24,
960
]
],
[
[
384,
24,
1499
],
[
1499,
2... | [
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Istradefylline"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u}... | Idelalisib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Istradefylline
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause ... |
DB00092 | DB00393 | 58 | 854 | [
"DDInter40",
"DDInter1295"
] | Alefacept | Nimodipine | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Moderate | 1 | [
[
[
58,
24,
854
]
],
[
[
58,
24,
84
],
[
84,
40,
854
]
],
[
[
58,
24,
478
],
[
478,
63,
854
]
],
[
[
58,
24,
1101
],
[
1101,
24,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nimodipine"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nisoldipine"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Nisoldipine and Nisoldipine (Compound) resembles Nimodipine (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could e... |
DB00515 | DB01181 | 589 | 1,532 | [
"DDInter387",
"DDInter906"
] | Cisplatin | Ifosfamide | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
589,
24,
1532
]
],
[
[
589,
5,
11659
],
[
11659,
44,
1532
]
],
[
[
589,
6,
6017
],
[
6017,
45,
1532
]
],
[
[
589,
21,
29209
],
[
29209... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Cisplatin",
"{u} (Compound) treats {v} (Disease)",
"testicular cancer"
],
[
"testicular cancer",
"{u} (Disease) i... | Cisplatin (Compound) treats testicular cancer (Disease) and testicular cancer (Disease) is treated by Ifosfamide (Compound)
Cisplatin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Ifosfamide (Compound)
Cisplatin (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Ifosfamide (... |
DB00328 | DB11095 | 831 | 235 | [
"DDInter921",
"DDInter505"
] | Indomethacin | Desirudin | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three dis... | Major | 2 | [
[
[
831,
25,
235
]
],
[
[
831,
24,
578
],
[
578,
24,
235
]
],
[
[
831,
24,
738
],
[
738,
63,
235
]
],
[
[
831,
25,
1409
],
[
1409,
2... | [
[
[
"Indomethacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagre... | Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Nira... |
DB00060 | DB00968 | 912 | 1,551 | [
"DDInter947",
"DDInter1185"
] | Interferon beta-1a | Methyldopa | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrener... | Moderate | 1 | [
[
[
912,
24,
1551
]
],
[
[
912,
63,
1648
],
[
1648,
24,
1551
]
],
[
[
912,
24,
267
],
[
267,
24,
1551
]
],
[
[
912,
24,
384
],
[
384,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyldopa"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Methyldopa
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Nal... |
DB00938 | DB08882 | 455 | 1,281 | [
"DDInter1635",
"DDInter1070"
] | Salmeterol | Linagliptin | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
455,
24,
1281
]
],
[
[
455,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
455,
6,
8374
],
[
8374,
45,
1281
]
],
[
[
455,
21,
28966
],
[
28966,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Salmeterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Salmeterol (Compound) causes Upper respiratory tract infection (... |
DB00539 | DB08912 | 11 | 1,040 | [
"DDInter1837",
"DDInter462"
] | Toremifene | Dabrafenib | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
11,
24,
1040
]
],
[
[
11,
6,
4973
],
[
4973,
45,
1040
]
],
[
[
11,
7,
17561
],
[
17561,
46,
1040
]
],
[
[
11,
18,
3887
],
[
3887,
... | [
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Toremifene",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Toremifene (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Toremifene (Compound) upregulates ORAI3 (Gene) and ORAI3 (Gene) is upregulated by Dabrafenib (Compound)
Toremifene (Compound) downregulates PRSS23 (Gene) and PRSS23 (Gene) is upregulated by Dabrafenib (Compound)
Toremifene (Comp... |
DB00279 | DB00398 | 1,152 | 79 | [
"DDInter1074",
"DDInter1702"
] | Liothyronine | Sorafenib | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Moderate | 1 | [
[
[
1152,
24,
79
]
],
[
[
1152,
6,
4973
],
[
4973,
45,
79
]
],
[
[
1152,
7,
13230
],
[
13230,
57,
79
]
],
[
[
1152,
21,
29170
],
[
29170,
... | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
]
],
[
[
"Liothyronine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)"... | Liothyronine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sorafenib (Compound)
Liothyronine (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is downregulated by Sorafenib (Compound)
Liothyronine (Compound) causes Cardiac failure congestive (Side Effect) and Cardiac failure congestive (Side Effect) i... |
DB00446 | DB00493 | 597 | 1,087 | [
"DDInter351",
"DDInter323"
] | Chloramphenicol | Cefotaxime | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under var... | Moderate | 1 | [
[
[
597,
24,
1087
]
],
[
[
597,
24,
164
],
[
164,
40,
1087
]
],
[
[
597,
24,
1305
],
[
1305,
1,
1087
]
],
[
[
597,
63,
149
],
[
149,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefotaxime"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefalotin"
],... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Cefalotin and Cefalotin (Compound) resembles Cefotaxime (Compound)
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Cefaclor and Cefaclor (Compound) resembles Cefotaxime (Compou... |
DB01064 | DB01365 | 1,148 | 280 | [
"DDInter987",
"DDInter1151"
] | Isoprenaline | Mephentermine | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | A sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type depen... | Moderate | 1 | [
[
[
1148,
24,
280
]
],
[
[
1148,
63,
551
],
[
551,
1,
280
]
],
[
[
1148,
63,
80
],
[
80,
40,
280
]
],
[
[
1148,
24,
93
],
[
93,
1,
... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephentermine"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
],
... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) resembles Mephentermine (Compound)
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine (Compound) resembles Mephentermine... |
DB00549 | DB06603 | 522 | 39 | [
"DDInter1955",
"DDInter1387"
] | Zafirlukast | Panobinostat | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Moderate | 1 | [
[
[
522,
24,
39
]
],
[
[
522,
24,
112
],
[
112,
23,
39
]
],
[
[
522,
23,
479
],
[
479,
23,
39
]
],
[
[
522,
63,
912
],
[
912,
24,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Donepezil and D... |
DB01083 | DB05528 | 1,142 | 1,070 | [
"DDInter1348",
"DDInter1228"
] | Orlistat | Mipomersen | The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical inter... | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Major | 2 | [
[
[
1142,
25,
1070
]
],
[
[
1142,
24,
384
],
[
384,
64,
1070
]
],
[
[
1142,
63,
1647
],
[
1647,
25,
1070
]
],
[
[
1142,
25,
1510
],
[
1510... | [
[
[
"Orlistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Orlistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
... | Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Mipomersen
Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may lead to a majo... |
DB01096 | DB01156 | 678 | 593 | [
"DDInter1356",
"DDInter252"
] | Oxamniquine | Bupropion | An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs. (From Martidale, The Ex... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Major | 2 | [
[
[
678,
25,
593
]
],
[
[
678,
6,
12523
],
[
12523,
45,
593
]
],
[
[
678,
62,
211
],
[
211,
23,
593
]
],
[
[
678,
24,
958
],
[
958,
... | [
[
[
"Oxamniquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Oxamniquine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Buprop... | Oxamniquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Bupropion (Compound)
Oxamniquine may cause a minor interaction that can limit clinical effects when taken with Tolterodine and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Bupropion
Oxamniquine may caus... |
DB00427 | DB00765 | 1,233 | 1,266 | [
"DDInter1879",
"DDInter1205"
] | Triprolidine | Metyrosine | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed) | Moderate | 1 | [
[
[
1233,
24,
1266
]
],
[
[
1233,
24,
662
],
[
662,
24,
1266
]
],
[
[
1233,
24,
401
],
[
401,
63,
1266
]
],
[
[
1233,
63,
999
],
[
999,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metyrosine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Metyrosine
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Promethazin... |
DB00307 | DB11003 | 1,101 | 748 | [
"DDInter202",
"DDInter100"
] | Bexarotene | Anthrax vaccine | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
1101,
24,
748
]
],
[
[
1101,
24,
322
],
[
322,
24,
748
]
],
[
[
1101,
62,
168
],
[
168,
24,
748
]
],
[
[
1101,
24,
564
],
[
564,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bor... |
DB00384 | DB00687 | 1,275 | 870 | [
"DDInter1859",
"DDInter747"
] | Triamterene | Fludrocortisone | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it a... | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
1275,
24,
870
]
],
[
[
1275,
24,
1220
],
[
1220,
40,
870
]
],
[
[
1275,
21,
28714
],
[
28714,
60,
870
]
],
[
[
1275,
24,
28
],
[
28,
... | [
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]... | Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Triamterene (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Fludrocortisone (Compound)
Triamterene may cause a mode... |
DB01166 | DB01175 | 477 | 318 | [
"DDInter379",
"DDInter672"
] | Cilostazol | Escitalopram | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Moderate | 1 | [
[
[
477,
24,
318
]
],
[
[
477,
63,
1230
],
[
1230,
1,
318
]
],
[
[
477,
6,
8374
],
[
8374,
45,
318
]
],
[
[
477,
18,
5587
],
[
5587,
... | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
... | Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Cilostazol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Escitalopram (Compound)
Cilostazol (Compound) downregulates SCAND1 (Gene) and SCAND1 (... |
DB00877 | DB01278 | 629 | 1,021 | [
"DDInter1678",
"DDInter1506"
] | Sirolimus | Pramlintide | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
629,
24,
1021
]
],
[
[
629,
63,
839
],
[
839,
24,
1021
]
],
[
[
629,
24,
35
],
[
35,
63,
1021
]
],
[
[
629,
25,
34
],
[
34,
63,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Grepafloxacin"
],
[
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol and Q... |
DB01082 | DB15066 | 1,448 | 445 | [
"DDInter1713",
"DDInter821"
] | Streptomycin | Givosiran | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a... | Moderate | 1 | [
[
[
1448,
24,
445
]
],
[
[
1448,
63,
1555
],
[
1555,
24,
445
]
],
[
[
1448,
24,
1272
],
[
1272,
24,
445
]
],
[
[
1448,
35,
416
],
[
416,
... | [
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
... | Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine and ... |
DB04868 | DB14730 | 478 | 1,412 | [
"DDInter1293",
"DDInter264"
] | Nilotinib | Calaspargase pegol | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
478,
24,
1412
]
],
[
[
478,
24,
792
],
[
792,
24,
1412
]
],
[
[
478,
63,
883
],
[
883,
24,
1412
]
],
[
[
478,
64,
322
],
[
322,
... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
],
... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and... |
DB01087 | DB11817 | 1,520 | 1,259 | [
"DDInter1520",
"DDInter165"
] | Primaquine | Baricitinib | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
1520,
25,
1259
]
],
[
[
1520,
63,
563
],
[
563,
24,
1259
]
],
[
[
1520,
24,
927
],
[
927,
24,
1259
]
],
[
[
1520,
64,
576
],
[
576,
... | [
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[
"Ganciclo... | Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and En... |
DB00749 | DB06441 | 59 | 936 | [
"DDInter699",
"DDInter283"
] | Etodolac | Cangrelor | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Moderate | 1 | [
[
[
59,
24,
936
]
],
[
[
59,
24,
477
],
[
477,
24,
936
]
],
[
[
59,
63,
305
],
[
305,
24,
936
]
],
[
[
59,
24,
738
],
[
738,
63,
... | [
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cangrelor"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"... | Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia c... |
DB00361 | DB15965 | 134 | 1,330 | [
"DDInter1939",
"DDInter1270"
] | Vinorelbine | Naxitamab | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Moderate | 1 | [
[
[
134,
24,
1330
]
],
[
[
134,
24,
1532
],
[
1532,
24,
1330
]
],
[
[
134,
63,
10
],
[
10,
24,
1330
]
],
[
[
134,
25,
770
],
[
770,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone ... |
DB01023 | DB08912 | 409 | 1,040 | [
"DDInter716",
"DDInter462"
] | Felodipine | Dabrafenib | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
409,
24,
1040
]
],
[
[
409,
6,
4973
],
[
4973,
45,
1040
]
],
[
[
409,
7,
6692
],
[
6692,
46,
1040
]
],
[
[
409,
21,
28900
],
[
28900,
... | [
[
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Felodipine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Felodipine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Felodipine (Compound) upregulates CGRRF1 (Gene) and CGRRF1 (Gene) is upregulated by Dabrafenib (Compound)
Felodipine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compou... |
DB00087 | DB05239 | 599 | 866 | [
"DDInter41",
"DDInter425"
] | Alemtuzumab | Cobimetinib | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Moderate | 1 | [
[
[
599,
24,
866
]
],
[
[
599,
24,
482
],
[
482,
24,
866
]
],
[
[
599,
24,
496
],
[
496,
63,
866
]
],
[
[
599,
63,
1253
],
[
1253,
2... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccin... |
DB09098 | DB11689 | 98 | 321 | [
"DDInter1700",
"DDInter1659"
] | Somatrem | Selumetinib | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate. Such discussion revolves around whether patients' natural dispo... | Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating ea... | Moderate | 1 | [
[
[
98,
24,
321
]
],
[
[
98,
63,
392
],
[
392,
24,
321
]
],
[
[
98,
24,
1297
],
[
1297,
63,
321
]
],
[
[
98,
64,
1101
],
[
1101,
24,... | [
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
... | Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodros... |
DB08868 | DB12240 | 1,011 | 110 | [
"DDInter737",
"DDInter1485"
] | Fingolimod | Polatuzumab vedotin | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Major | 2 | [
[
[
1011,
25,
110
]
],
[
[
1011,
25,
129
],
[
129,
23,
110
]
],
[
[
1011,
64,
1419
],
[
1419,
24,
110
]
],
[
[
1011,
62,
578
],
[
578,
... | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",... | Fingolimod may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Polatuzumab vedotin
Fingolimod may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a modera... |
DB00604 | DB01242 | 1,425 | 1,237 | [
"DDInter385",
"DDInter410"
] | Cisapride | Clomipramine | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Major | 2 | [
[
[
1425,
25,
1237
]
],
[
[
1425,
25,
684
],
[
684,
1,
1237
]
],
[
[
1425,
64,
216
],
[
216,
1,
1237
]
],
[
[
1425,
25,
401
],
[
401,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clomipramine"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{... | Cisapride may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Cisapride may lead to a major life threatening interaction when taken with Chlorpromazine and Chlorpromazine (Compound) resembles Clomipramine (Compound)
Cisapride may le... |
DB01118 | DB11703 | 33 | 405 | [
"DDInter76",
"DDInter9"
] | Amiodarone | Acalabrutinib | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
33,
24,
405
]
],
[
[
33,
63,
1324
],
[
1324,
24,
405
]
],
[
[
33,
24,
1446
],
[
1446,
24,
405
]
],
[
[
33,
25,
982
],
[
982,
63,... | [
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
... | Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide and... |
DB00427 | DB00555 | 1,233 | 706 | [
"DDInter1879",
"DDInter1020"
] | Triprolidine | Lamotrigine | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It... | Moderate | 1 | [
[
[
1233,
24,
706
]
],
[
[
1233,
24,
530
],
[
530,
24,
706
]
],
[
[
1233,
24,
100
],
[
100,
63,
706
]
],
[
[
1233,
63,
1594
],
[
1594,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lamotrigine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Lamotrigine
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine ... |
DB00108 | DB14811 | 1,066 | 385 | [
"DDInter1268",
"DDInter979"
] | Natalizumab | Isatuximab | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic an... | Major | 2 | [
[
[
1066,
25,
385
]
],
[
[
1066,
25,
1362
],
[
1362,
24,
385
]
],
[
[
1066,
64,
599
],
[
599,
24,
385
]
],
[
[
1066,
24,
1430
],
[
1430,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isatuximab"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may... | Natalizumab may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Natalizumab may lead to a major life threatening interaction when taken with Alemtuzumab and Alemtuzumab may cause a moderate inte... |
DB05316 | DB09054 | 749 | 384 | [
"DDInter1467",
"DDInter905"
] | Pimavanserin | Idelalisib | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Major | 2 | [
[
[
749,
25,
384
]
],
[
[
749,
25,
1618
],
[
1618,
24,
384
]
],
[
[
749,
63,
888
],
[
888,
24,
384
]
],
[
[
749,
24,
1228
],
[
1228,
... | [
[
[
"Pimavanserin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Pimavanserin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
... | Pimavanserin may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may ... |
DB00289 | DB11730 | 847 | 351 | [
"DDInter132",
"DDInter1588"
] | Atomoxetine | Ribociclib | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
847,
25,
351
]
],
[
[
847,
23,
112
],
[
112,
23,
351
]
],
[
[
847,
24,
283
],
[
283,
62,
351
]
],
[
[
847,
24,
355
],
[
355,
24,... | [
[
[
"Atomoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Atomoxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Atomoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fe... |
DB00353 | DB01612 | 588 | 1,637 | [
"DDInter1187",
"DDInter92"
] | Methylergometrine | Amyl Nitrite | A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed) | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Moderate | 1 | [
[
[
588,
24,
1637
]
],
[
[
588,
40,
628
],
[
628,
24,
1637
]
],
[
[
588,
1,
469
],
[
469,
24,
1637
]
],
[
[
588,
40,
628
],
[
628,
1... | [
[
[
"Methylergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Methylergometrine",
"{u} (Compound) resembles {v} (Compound)",
"Ergometrine"
],
[
"Ergometrine",
"{u} m... | Methylergometrine (Compound) resembles Ergometrine (Compound) and Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Methylergometrine (Compound) resembles Bromocriptine (Compound) and Bromocriptine may cause a moderate interaction that could exacerbate diseases whe... |
DB00434 | DB09272 | 13 | 412 | [
"DDInter459",
"DDInter632"
] | Cyproheptadine | Eluxadoline | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
13,
24,
412
]
],
[
[
13,
63,
1594
],
[
1594,
24,
412
]
],
[
[
13,
24,
543
],
[
543,
24,
412
]
],
[
[
13,
74,
21
],
[
21,
24,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide a... |
DB00372 | DB09034 | 999 | 1,313 | [
"DDInter1793",
"DDInter1733"
] | Thiethylperazine | Suvorexant | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Moderate | 1 | [
[
[
999,
24,
1313
]
],
[
[
999,
24,
530
],
[
530,
24,
1313
]
],
[
[
999,
63,
701
],
[
701,
24,
1313
]
],
[
[
999,
25,
1311
],
[
1311,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Clemastin... |
DB00980 | DB11186 | 969 | 1,609 | [
"DDInter1564",
"DDInter1427"
] | Ramelteon | Pentoxyverine | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
969,
24,
1609
]
],
[
[
969,
63,
104
],
[
104,
24,
1609
]
],
[
[
969,
24,
649
],
[
649,
24,
1609
]
],
[
[
969,
64,
475
],
[
475,
... | [
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[... | Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and C... |
DB00879 | DB09122 | 1,279 | 1,613 | [
"DDInter637",
"DDInter1409"
] | Emtricitabine | Peginterferon beta-1a | Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults or combined with [tenofovir alafenamide] for the prevention of HIV-1 infection in high risk adolescents and adults. Emtricitabine is a cytidine analogue. The drug works by inhibiting HIV reverse t... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
1279,
24,
1613
]
],
[
[
1279,
63,
267
],
[
267,
24,
1613
]
],
[
[
1279,
24,
1142
],
[
1142,
24,
1613
]
],
[
[
1279,
25,
1377
],
[
1377... | [
[
[
"Emtricitabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Emtricitabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone... | Emtricitabine may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Emtricitabine may cause a moderate interaction that could exacerbate diseases when taken with Orli... |
DB00397 | DB08907 | 1,466 | 1,344 | [
"DDInter1458",
"DDInter280"
] | Phenylpropanolamine | Canagliflozin | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
1466,
24,
1344
]
],
[
[
1466,
24,
549
],
[
549,
1,
1344
]
],
[
[
1466,
21,
28681
],
[
28681,
60,
1344
]
],
[
[
1466,
35,
1445
],
[
144... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagl... | Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Phenylpropanolamine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Canagliflozin (Compound)
... |
DB08871 | DB09082 | 36 | 659 | [
"DDInter666",
"DDInter1934"
] | Eribulin | Vilanterol | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
36,
24,
659
]
],
[
[
36,
63,
1570
],
[
1570,
24,
659
]
],
[
[
36,
24,
927
],
[
927,
63,
659
]
],
[
[
36,
64,
1069
],
[
1069,
24,... | [
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
],
[
... | Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encor... |
DB09135 | DB15066 | 1,211 | 445 | [
"DDInter967",
"DDInter821"
] | Ioxilan | Givosiran | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a... | Major | 2 | [
[
[
1211,
25,
445
]
],
[
[
1211,
64,
589
],
[
589,
24,
445
]
],
[
[
1211,
64,
629
],
[
629,
25,
445
]
],
[
[
1211,
64,
589
],
[
589,
... | [
[
[
"Ioxilan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Givosiran"
]
],
[
[
"Ioxilan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may cause ... | Ioxilan may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Ioxilan may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may lead to a major life threatening... |
DB00352 | DB01005 | 482 | 995 | [
"DDInter1814",
"DDInter894"
] | Tioguanine | Hydroxyurea | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Moderate | 1 | [
[
[
482,
24,
995
]
],
[
[
482,
5,
11555
],
[
11555,
44,
995
]
],
[
[
482,
21,
28722
],
[
28722,
60,
995
]
],
[
[
482,
23,
1299
],
[
1299,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Tioguanine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disea... | Tioguanine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Hydroxyurea (Compound)
Tioguanine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Hydroxyurea (Compound)
Tioguanine may cause a minor interaction that can limit clinical effects when tak... |
DB00831 | DB00927 | 1,178 | 1,559 | [
"DDInter1866",
"DDInter712"
] | Trifluoperazine | Famotidine | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Moderate | 1 | [
[
[
1178,
24,
1559
]
],
[
[
1178,
18,
7359
],
[
7359,
57,
1559
]
],
[
[
1178,
21,
28826
],
[
28826,
60,
1559
]
],
[
[
1178,
23,
1384
],
[
... | [
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) downregulates {v} (Gene)",
"TXNDC9"
],
[
"TXNDC9",
"{u} (Gene) is downreg... | Trifluoperazine (Compound) downregulates TXNDC9 (Gene) and TXNDC9 (Gene) is downregulated by Famotidine (Compound)
Trifluoperazine (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Famotidine (Compound)
Trifluoperazine may cause a minor interaction that can limit clinical effects when tak... |
DB00334 | DB06595 | 867 | 1,491 | [
"DDInter1326",
"DDInter1214"
] | Olanzapine | Midostaurin | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
867,
24,
1491
]
],
[
[
867,
23,
112
],
[
112,
23,
1491
]
],
[
[
867,
24,
761
],
[
761,
24,
1491
]
],
[
[
867,
24,
1662
],
[
1662,
... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Olanzapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Olanzapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Sa... |
DB00774 | DB09564 | 1,577 | 1,296 | [
"DDInter889",
"DDInter930"
] | Hydroflumethiazide | Insulin degludec | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1577,
24,
1296
]
],
[
[
1577,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
1577,
63,
1645
],
[
1645,
24,
1296
]
],
[
[
1577,
40,
674
],
[
674... | [
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbu... | Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00333 | DB00400 | 576 | 353 | [
"DDInter1166",
"DDInter843"
] | Methadone | Griseofulvin | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Moderate | 1 | [
[
[
576,
24,
353
]
],
[
[
576,
6,
8374
],
[
8374,
45,
353
]
],
[
[
576,
21,
28746
],
[
28746,
60,
353
]
],
[
[
576,
63,
1101
],
[
1101,
... | [
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
]
],
[
[
"Methadone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Methadone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Griseofulvin (Compound)
Methadone (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Griseofulvin (Compound)
Methadone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexar... |
DB00106 | DB12245 | 618 | 823 | [
"DDInter4",
"DDInter1863"
] | Abarelix | Triclabendazole | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
618,
24,
823
]
],
[
[
618,
23,
1247
],
[
1247,
23,
823
]
],
[
[
618,
24,
1612
],
[
1612,
24,
823
]
],
[
[
618,
24,
1619
],
[
1619,
... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Abarelix may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir ... |
DB00564 | DB05239 | 1,236 | 866 | [
"DDInter293",
"DDInter425"
] | Carbamazepine | Cobimetinib | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Major | 2 | [
[
[
1236,
25,
866
]
],
[
[
1236,
25,
214
],
[
214,
63,
866
]
],
[
[
1236,
63,
1051
],
[
1051,
24,
866
]
],
[
[
1236,
24,
888
],
[
888,
... | [
[
[
"Carbamazepine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
]
],
[
[
"Carbamazepine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
... | Carbamazepine may lead to a major life threatening interaction when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Ami... |
DB00912 | DB00963 | 473 | 1,263 | [
"DDInter1581",
"DDInter241"
] | Repaglinide | Bromfenac | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool f... | Moderate | 1 | [
[
[
473,
24,
1263
]
],
[
[
473,
24,
935
],
[
935,
40,
1263
]
],
[
[
473,
63,
831
],
[
831,
40,
1263
]
],
[
[
473,
63,
1512
],
[
1512,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
],
[
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen (Compound) resembles Bromfenac (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) resembles Bromfenac (Compou... |
DB06215 | DB14491 | 1,353 | 428 | [
"DDInter730",
"DDInter725"
] | Ferumoxytol | Ferrous fumarate | Ferumoxytol is an intravenously administered iron preparation indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). It is comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isoton... | Used in treatment of iron deficiency anemia. | Moderate | 1 | [
[
[
1353,
24,
428
]
],
[
[
1353,
63,
597
],
[
597,
24,
428
]
],
[
[
1353,
25,
1575
],
[
1575,
25,
428
]
],
[
[
1353,
63,
597
],
[
597,
... | [
[
[
"Ferumoxytol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Ferumoxytol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
... | Ferumoxytol may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate
Ferumoxytol may lead to a major life threatening interaction when taken with Dimercaprol and Di... |
DB08907 | DB09080 | 1,344 | 144 | [
"DDInter280",
"DDInter1331"
] | Canagliflozin | Olodaterol | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1344,
24,
144
]
],
[
[
1344,
63,
956
],
[
956,
24,
144
]
],
[
[
1344,
24,
1399
],
[
1399,
63,
144
]
],
[
[
1344,
64,
246
],
[
246,
... | [
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norfloxacin"
],
... | Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbo... |
DB00087 | DB00688 | 599 | 955 | [
"DDInter41",
"DDInter1251"
] | Alemtuzumab | Mycophenolate mofetil | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, ren... | Moderate | 1 | [
[
[
599,
24,
955
]
],
[
[
599,
24,
1096
],
[
1096,
40,
955
]
],
[
[
599,
63,
1184
],
[
1184,
24,
955
]
],
[
[
599,
24,
713
],
[
713,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolate mofetil"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic a... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid (Compound) resembles Mycophenolate mofetil (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate... |
DB00188 | DB00951 | 168 | 1,072 | [
"DDInter222",
"DDInter986"
] | Bortezomib | Isoniazid | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Moderate | 1 | [
[
[
168,
24,
1072
]
],
[
[
168,
6,
8374
],
[
8374,
45,
1072
]
],
[
[
168,
21,
28722
],
[
28722,
60,
1072
]
],
[
[
168,
23,
1220
],
[
1220,... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
]
],
[
[
"Bortezomib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Bortezomib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Isoniazid (Compound)
Bortezomib (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Isoniazid (Compound)
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethaso... |
DB01182 | DB01268 | 371 | 1,151 | [
"DDInter1534",
"DDInter1731"
] | Propafenone | Sunitinib | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
371,
24,
1151
]
],
[
[
371,
6,
4973
],
[
4973,
45,
1151
]
],
[
[
371,
7,
16192
],
[
16192,
46,
1151
]
],
[
[
371,
21,
29269
],
[
29269... | [
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Propafenone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Propafenone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sunitinib (Compound)
Propafenone (Compound) upregulates KIAA0355 (Gene) and KIAA0355 (Gene) is upregulated by Sunitinib (Compound)
Propafenone (Compound) causes Menopausal symptoms (Side Effect) and Menopausal symptoms (Side Effect) is caused by Sun... |
DB00604 | DB01211 | 1,425 | 609 | [
"DDInter385",
"DDInter393"
] | Cisapride | Clarithromycin | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Major | 2 | [
[
[
1425,
25,
609
]
],
[
[
1425,
64,
1570
],
[
1570,
24,
609
]
],
[
[
1425,
6,
7524
],
[
7524,
45,
609
]
],
[
[
1425,
64,
600
],
[
600,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Azithromycin"
],
[
"Azithromycin",
... | Cisapride may lead to a major life threatening interaction when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Cisapride (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Clarithromycin (Compound)
Cisapride may lead to a... |
DB00331 | DB00777 | 1,645 | 146 | [
"DDInter1164",
"DDInter1537"
] | Metformin | Propiomazine | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Struct... | Moderate | 1 | [
[
[
1645,
24,
146
]
],
[
[
1645,
24,
508
],
[
508,
1,
146
]
],
[
[
1645,
24,
401
],
[
401,
63,
146
]
],
[
[
1645,
24,
104
],
[
104,
... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Propiomazine (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that cou... |
DB12095 | DB15091 | 179 | 676 | [
"DDInter1760",
"DDInter1901"
] | Telotristat ethyl | Upadacitinib | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Moderate | 1 | [
[
[
179,
24,
676
]
],
[
[
179,
24,
283
],
[
283,
24,
676
]
],
[
[
179,
63,
1593
],
[
1593,
24,
676
]
],
[
[
179,
25,
1017
],
[
1017,
... | [
[
[
"Telotristat ethyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Telotristat ethyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"... | Telotristat ethyl may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Telotristat ethyl may cause a moderate interaction that could exacerbate diseases when taken with Crizo... |
DB00468 | DB00489 | 1,424 | 17 | [
"DDInter1557",
"DDInter1704"
] | Quinine | Sotalol | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Major | 2 | [
[
[
1424,
25,
17
]
],
[
[
1424,
64,
347
],
[
347,
40,
17
]
],
[
[
1424,
6,
3958
],
[
3958,
45,
17
]
],
[
[
1424,
21,
29648
],
[
29648,
... | [
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibutilide"
],
[
"Ibutilide",
"{u} (Compound) r... | Quinine may lead to a major life threatening interaction when taken with Ibutilide and Ibutilide (Compound) resembles Sotalol (Compound)
Quinine (Compound) binds KCNH2 (Gene) and KCNH2 (Gene) is bound by Sotalol (Compound)
Quinine (Compound) causes Disorientation (Side Effect) and Disorientation (Side Effect) is caused... |
DB00238 | DB13074 | 188 | 877 | [
"DDInter1285",
"DDInter1110"
] | Nevirapine | Macimorelin | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Moderate | 1 | [
[
[
188,
24,
877
]
],
[
[
188,
24,
1320
],
[
1320,
24,
877
]
],
[
[
188,
25,
1019
],
[
1019,
24,
877
]
],
[
[
188,
23,
1101
],
[
1101,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
... | Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Nevirapine may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a... |
DB06688 | DB11569 | 1,430 | 1,093 | [
"DDInter1677",
"DDInter1003"
] | Sipuleucel-T | Ixekizumab | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflamma... | Moderate | 1 | [
[
[
1430,
24,
1093
]
],
[
[
1430,
63,
66
],
[
66,
24,
1093
]
],
[
[
1430,
24,
975
],
[
975,
63,
1093
]
],
[
[
1430,
24,
713
],
[
713,
... | [
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
... | Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin and... |
DB00758 | DB00951 | 1,347 | 1,072 | [
"DDInter413",
"DDInter986"
] | Clopidogrel | Isoniazid | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Moderate | 1 | [
[
[
1347,
24,
1072
]
],
[
[
1347,
6,
8374
],
[
8374,
45,
1072
]
],
[
[
1347,
21,
29435
],
[
29435,
60,
1072
]
],
[
[
1347,
25,
1130
],
[
1... | [
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
]
],
[
[
"Clopidogrel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Clopidogrel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Isoniazid (Compound)
Clopidogrel (Compound) causes Epigastric distress (Side Effect) and Epigastric distress (Side Effect) is caused by Isoniazid (Compound)
Clopidogrel may lead to a major life threatening interaction when taken with Pioglitazone ... |
DB00060 | DB13873 | 912 | 1,534 | [
"DDInter947",
"DDInter719"
] | Interferon beta-1a | Fenofibric acid | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L128... | Moderate | 1 | [
[
[
912,
24,
1534
]
],
[
[
912,
24,
267
],
[
267,
24,
1534
]
],
[
[
912,
63,
305
],
[
305,
24,
1534
]
],
[
[
912,
24,
126
],
[
126,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenofibric acid"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltre... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00048 | DB06228 | 1,595 | 792 | [
"DDInter435",
"DDInter1609"
] | Collagenase clostridium histolyticum | Rivaroxaban | Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum. It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and Peyronie's disease. The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ... | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Moderate | 1 | [
[
[
1595,
24,
792
]
],
[
[
1595,
24,
885
],
[
885,
25,
792
]
],
[
[
1595,
63,
25
],
[
25,
25,
792
]
],
[
[
1595,
24,
802
],
[
802,
6... | [
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases whe... | Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may lead to a major life threatening interaction when taken with Rivaroxaban
Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate dise... |
DB00835 | DB00962 | 100 | 1,639 | [
"DDInter245",
"DDInter1957"
] | Brompheniramine | Zaleplon | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States. | Moderate | 1 | [
[
[
100,
24,
1639
]
],
[
[
100,
6,
8374
],
[
8374,
45,
1639
]
],
[
[
100,
63,
13
],
[
13,
24,
1639
]
],
[
[
100,
24,
1609
],
[
1609,
... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zaleplon"
]
],
[
[
"Brompheniramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Com... | Brompheniramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zaleplon (Compound)
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Zaleplon
Brom... |
DB00328 | DB06715 | 831 | 239 | [
"DDInter921",
"DDInter1500"
] | Indomethacin | Potassium Iodide | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Saturated solution of Potassium Iodide (SSKI) is used pharmaceutically for emergency use in patients experiencing acute symptoms of severe hyperthyroidism (also known as thyroid storm or thyrotoxic crisis). SSKI can also be used for radioiodine-contamination emergencies or in preparation of thyrotoxic patients for thyr... | Moderate | 1 | [
[
[
831,
24,
239
]
],
[
[
831,
21,
29196
],
[
29196,
60,
239
]
],
[
[
831,
40,
1263
],
[
1263,
24,
239
]
],
[
[
831,
24,
877
],
[
877,
... | [
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium Iodide"
]
],
[
[
"Indomethacin",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side... | Indomethacin (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Potassium Iodide (Compound)
Indomethacin (Compound) resembles Bromfenac (Compound) and Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Potassium Iodide
Indomethacin may cause a... |
DB00357 | DB01268 | 1,051 | 1,151 | [
"DDInter71",
"DDInter1731"
] | Aminoglutethimide | Sunitinib | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
1051,
24,
1151
]
],
[
[
1051,
6,
8374
],
[
8374,
45,
1151
]
],
[
[
1051,
18,
20102
],
[
20102,
57,
1151
]
],
[
[
1051,
21,
29209
],
[
... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Aminoglutethimide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v}... | Aminoglutethimide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sunitinib (Compound)
Aminoglutethimide (Compound) downregulates FAM57A (Gene) and FAM57A (Gene) is downregulated by Sunitinib (Compound)
Aminoglutethimide (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Sunit... |
DB01087 | DB01236 | 1,520 | 679 | [
"DDInter1520",
"DDInter1664"
] | Primaquine | Sevoflurane | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Moderate | 1 | [
[
[
1520,
24,
679
]
],
[
[
1520,
63,
1262
],
[
1262,
40,
679
]
],
[
[
1520,
6,
8374
],
[
8374,
45,
679
]
],
[
[
1520,
21,
28658
],
[
28658... | [
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sevoflurane"
]
],
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perflutren"
],
[
... | Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Perflutren and Perflutren (Compound) resembles Sevoflurane (Compound)
Primaquine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sevoflurane (Compound)
Primaquine (Compound) causes Vomiting (Side Effect) and Vomiting... |
DB00836 | DB01591 | 543 | 667 | [
"DDInter1088",
"DDInter1696"
] | Loperamide | Solifenacin | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
543,
24,
667
]
],
[
[
543,
6,
8374
],
[
8374,
45,
667
]
],
[
[
543,
21,
28703
],
[
28703,
60,
667
]
],
[
[
543,
24,
112
],
[
112,
... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Loperamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Loperamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Solifenacin (Compound)
Loperamide (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Solifenacin (Compound)
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and M... |
DB00860 | DB01319 | 891 | 34 | [
"DDInter1513",
"DDInter777"
] | Prednisolone | Fosamprenavir | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Moderate | 1 | [
[
[
891,
24,
34
]
],
[
[
891,
63,
1091
],
[
1091,
40,
34
]
],
[
[
891,
6,
8374
],
[
8374,
45,
34
]
],
[
[
891,
21,
28661
],
[
28661,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],
... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir (Compound) resembles Fosamprenavir (Compound)
Prednisolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fosamprenavir (Compound)
Prednisolone (Compound) causes Acute coronary syndrome (... |
DB00317 | DB00704 | 883 | 267 | [
"DDInter810",
"DDInter1263"
] | Gefitinib | Naltrexone | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Moderate | 1 | [
[
[
883,
24,
267
]
],
[
[
883,
6,
4973
],
[
4973,
45,
267
]
],
[
[
883,
7,
3163
],
[
3163,
46,
267
]
],
[
[
883,
18,
20113
],
[
20113,
... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Gefitinib",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Gefitinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Naltrexone (Compound)
Gefitinib (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Naltrexone (Compound)
Gefitinib (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Naltrexone (Compound)
Gefitinib (Compou... |
DB00065 | DB05239 | 581 | 866 | [
"DDInter923",
"DDInter425"
] | Infliximab | Cobimetinib | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Major | 2 | [
[
[
581,
25,
866
]
],
[
[
581,
25,
482
],
[
482,
24,
866
]
],
[
[
581,
24,
33
],
[
33,
24,
866
]
],
[
[
581,
24,
496
],
[
496,
63,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} ... | Infliximab may lead to a major life threatening interaction when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone may cause... |
DB00401 | DB06273 | 84 | 980 | [
"DDInter1298",
"DDInter1824"
] | Nisoldipine | Tocilizumab | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Moderate | 1 | [
[
[
84,
24,
980
]
],
[
[
84,
40,
1428
],
[
1428,
24,
980
]
],
[
[
84,
1,
336
],
[
336,
24,
980
]
],
[
[
84,
62,
1031
],
[
1031,
24,
... | [
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Nisoldipine",
"{u} (Compound) resembles {v} (Compound)",
"Isradipine"
],
[
"Isradipine",
"{u} may cause a mode... | Nisoldipine (Compound) resembles Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Nisoldipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizu... |
DB00619 | DB01357 | 1,419 | 890 | [
"DDInter909",
"DDInter1160"
] | Imatinib | Mestranol | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives. | Moderate | 1 | [
[
[
1419,
24,
890
]
],
[
[
1419,
24,
1197
],
[
1197,
40,
890
]
],
[
[
1419,
63,
380
],
[
380,
40,
890
]
],
[
[
1419,
63,
506
],
[
506,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norethisterone"
],
[
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) resembles Mestranol (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens (Compound) resembles... |
DB08822 | DB11130 | 911 | 407 | [
"DDInter156",
"DDInter1344"
] | Azilsartan medoxomil | Opium | Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in ... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
911,
24,
407
]
],
[
[
911,
63,
104
],
[
104,
24,
407
]
],
[
[
911,
40,
217
],
[
217,
24,
407
]
],
[
[
911,
24,
1662
],
[
1662,
2... | [
[
[
"Azilsartan medoxomil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Azilsartan medoxomil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine... | Azilsartan medoxomil may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Azilsartan medoxomil (Compound) resembles Olmesartan (Compound) and Olmesartan may cause a moderate int... |
DB00087 | DB15044 | 599 | 631 | [
"DDInter41",
"DDInter1738"
] | Alemtuzumab | Tafasitamab | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytoto... | Moderate | 1 | [
[
[
599,
24,
631
]
],
[
[
599,
24,
4
],
[
4,
24,
631
]
],
[
[
599,
63,
1184
],
[
1184,
24,
631
]
],
[
[
599,
25,
976
],
[
976,
25,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafasitamab"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinat... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Tafasitamab
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when... |
DB09134 | DB14598 | 1,552 | 183 | [
"DDInter966",
"DDInter619"
] | Ioversol | Edetate calcium disodium anhydrous | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol,... | Edetate calcium disodium is a metal ion chelator used to reduce blood concentrations and depot stores of lead from the body. It is on the World Health Organization Model List of Essential Medicines. Edetate calcium disodium was granted FDA approval on 16 July 1953. | Major | 2 | [
[
[
1552,
25,
183
]
],
[
[
1552,
64,
372
],
[
372,
24,
183
]
],
[
[
1552,
64,
789
],
[
789,
24,
372
],
[
372,
24,
183
]
],
[
[
1552,
... | [
[
[
"Ioversol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edetate calcium disodium anhydrous"
]
],
[
[
"Ioversol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clofarabine"
],
[
"Clof... | Ioversol may lead to a major life threatening interaction when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Edetate calcium disodium anhydrous
Ioversol may lead to a major life threatening interaction when taken with Foscarnet and Foscarnet may c... |
DB06663 | DB08907 | 1,154 | 1,344 | [
"DDInter1398",
"DDInter280"
] | Pasireotide | Canagliflozin | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
1154,
24,
1344
]
],
[
[
1154,
63,
549
],
[
549,
1,
1344
]
],
[
[
1154,
21,
29013
],
[
29013,
60,
1344
]
],
[
[
1154,
64,
739
],
[
739,... | [
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Pasireotide (Compound) causes Diabetes mellitus (Side Effect) and Diabetes mellitus (Side Effect) is caused by Canagliflozin (Compound)
Pasireotide ma... |
DB00295 | DB00347 | 475 | 917 | [
"DDInter1244",
"DDInter1871"
] | Morphine | Trimethadione | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378) | Moderate | 1 | [
[
[
475,
24,
917
]
],
[
[
475,
6,
3486
],
[
3486,
45,
917
]
],
[
[
475,
21,
28769
],
[
28769,
60,
917
]
],
[
[
475,
24,
401
],
[
401,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethadione"
]
],
[
[
"Morphine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
... | Morphine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Trimethadione (Compound)
Morphine (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Trimethadione (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Prome... |
DB00440 | DB00682 | 1,548 | 126 | [
"DDInter1874",
"DDInter1951"
] | Trimethoprim | Warfarin | Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival. Trimethoprim is often used in comb... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Moderate | 1 | [
[
[
1548,
24,
126
]
],
[
[
1548,
6,
3486
],
[
3486,
45,
126
]
],
[
[
1548,
25,
663
],
[
663,
23,
126
]
],
[
[
1548,
24,
328
],
[
328,
... | [
[
[
"Trimethoprim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Trimethoprim",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)... | Trimethoprim (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Warfarin (Compound)
Trimethoprim may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Warfarin
Trimethoprim may cause a modera... |
DB00726 | DB08899 | 1,164 | 129 | [
"DDInter1876",
"DDInter649"
] | Trimipramine | Enzalutamide | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1164,
24,
129
]
],
[
[
1164,
24,
918
],
[
918,
1,
129
]
],
[
[
1164,
6,
8374
],
[
8374,
45,
129
]
],
[
[
1164,
21,
28703
],
[
28703,
... | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Trimipramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Trimipramine (Compound) causes Pruritus (Side Effect) ... |
DB04837 | DB04908 | 649 | 1,671 | [
"DDInter407",
"DDInter741"
] | Clofedanol | Flibanserin | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Moderate | 1 | [
[
[
649,
24,
1671
]
],
[
[
649,
63,
1594
],
[
1594,
24,
1671
]
],
[
[
649,
1,
832
],
[
832,
24,
1671
]
],
[
[
649,
24,
407
],
[
407,
... | [
[
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Clofedanol (Compound) resembles Tripelennamine (Compound) and Tripelennamine may cause a moderate interaction t... |
DB01281 | DB15762 | 881 | 725 | [
"DDInter5",
"DDInter1644"
] | Abatacept | Satralizumab | Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS mo... | Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare au... | Major | 2 | [
[
[
881,
25,
725
]
],
[
[
881,
23,
1193
],
[
1193,
23,
725
]
],
[
[
881,
24,
713
],
[
713,
24,
725
]
],
[
[
881,
63,
58
],
[
58,
24,... | [
[
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Satralizumab"
]
],
[
[
"Abatacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc glu... | Abatacept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Satralizumab
Abatacept may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate... |
DB00388 | DB09045 | 1,636 | 52 | [
"DDInter1453",
"DDInter607"
] | Phenylephrine | Dulaglutide | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
1636,
24,
52
]
],
[
[
1636,
24,
170
],
[
170,
23,
52
]
],
[
[
1636,
63,
73
],
[
73,
24,
52
]
],
[
[
1636,
24,
1296
],
[
1296,
63... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
... | Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine an... |
DB00450 | DB00719 | 78 | 1,219 | [
"DDInter603",
"DDInter149"
] | Droperidol | Azatadine | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Moderate | 1 | [
[
[
78,
24,
1219
]
],
[
[
78,
63,
13
],
[
13,
24,
1219
]
],
[
[
78,
24,
830
],
[
830,
1,
1219
]
],
[
[
78,
24,
543
],
[
543,
63,
... | [
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[... | Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine a... |
DB00678 | DB00902 | 240 | 104 | [
"DDInter1095",
"DDInter1168"
] | Losartan | Methdilazine | Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough simila... | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
240,
24,
104
]
],
[
[
240,
24,
820
],
[
820,
1,
104
]
],
[
[
240,
24,
401
],
[
401,
63,
104
]
],
[
[
240,
63,
475
],
[
475,
24,
... | [
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
... | Losartan may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Losartan may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that c... |
DB08815 | DB12141 | 154 | 971 | [
"DDInter1104",
"DDInter817"
] | Lurasidone | Gilteritinib | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
154,
24,
971
]
],
[
[
154,
24,
466
],
[
466,
62,
971
]
],
[
[
154,
63,
820
],
[
820,
24,
971
]
],
[
[
154,
25,
283
],
[
283,
63,... | [
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
... | Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and A... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.